Slovenská chirurgia 2/2012

Ertapenem in first line antibiotic monotherapy for inflammatory acute abdomen

Aim: Evaluation of clinical efectivity of ertapenem (type I. carbapenem antibiotic) monotherapy of community acquired intraabdominal infections in acute abdomen. Material and methods: We retrospectively evaluated 52 patients treated for acute abdomen (inflamatory and perforation) over 16 months in 2011-2012 using ertapenem monotherapy as first line antibiotic. We also evaluated microbiological findings and presence of polyresistant pathogens. Results: Overall efficacy of antibiotic treatment was 86,5%, with complication rates and mortality rates of 40,4% and 3,8% respectively. Average hospital stay was 10,4 (±6,04) days, average antibiotic treatment 6,8 (±3,01) days. Most frequent pathogens were E. coli and Streptococcus sp. ESBL producing microorganisms were detected in 2 patients. 4 of 5 patients with detected Pseudomonas aeruginosa did not reqiure augmentation of antibiotic regime. Results: In accordance with current literature, ertapenem monotherapy is effective and represents an equal alternative for currently used combination regimes.

Keywords: community acquired intraabdominal infections, ertapenem, monotherapy, first line antibiotic therapy.